Physician profile
Martin E Keisch
NPI 1326018037
$319,309.36
in general payments reported to CMS, 2019-2025
11 companies · $310 in 2025
The $310 reported for 2025 was more than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $60K · 2020: $78K · 2021: $54K · 2022: $72K · 2023: $54K · 2025: $310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $54K · Food and Beverage: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $54,000.00 |
| Food and Beverage | $356.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic INC | $174,000.00 | 2019-2023 | Mammosite |
| Focal Therapeutics, INC. | $132,000.00 | 2019-2021 | |
| Bioptics, INC. | $12,000.00 | 2020 | |
| Accuray Incorporated | $430.38 | 2019-2021 | |
| Telix Pharmaceuticals | $309.61 | 2025 | Illuccix |
| Siemens Medical Solutions USA, INC. | $135.18 | 2022 | |
| Dendreon Pharmaceuticals LLC | $129.61 | 2019 | |
| Genentech USA, INC. | $119.73 | 2019 | |
| Allergan, INC. | $108.94 | 2019 | |
| Boston Scientific Corporation | $46.50 | 2023 | Spaceoar Vue System - 10ml |
| Palette Life Sciences, INC. | $29.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Keisch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.